Intended for healthcare professionals


Fracture risk a class effect of thiazolidinediones in women

BMJ 2007; 334 doi: (Published 15 March 2007) Cite this as: BMJ 2007;334:551
  1. Robert Short
  1. London

    Treatment with thiazolidinediones (glitazones) for type 2 diabetes has been found to increase the risk of fractures in women. Pioglitazone has now joined rosiglitazone, as the subject of a US Food and Drug Administration alert for fracture risk.

    Takeda, the makers of pioglitazone (contained in Actos, Actosplusmet, and Duetact), and GlaxoSmithKline, the makers of rosiglitazone (contained in Avandia and Avandamet), have contacted US healthcare professionals setting out the evidence on fracture risk and recommending that they consider this risk when starting or treating women with type 2 diabetes with these agents.

    The statement on pioglitazone …

    View Full Text

    Log in

    Log in through your institution


    * For online subscription